Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Books
  • Technology
  • Manufacturing
  • Health
  • Financial
  • Artificial Intelligence
ncarol.com

Curtana Pharmaceuticals Signs Development and Manufacturing Agreement with Catalent for Brain Cancer Drug CT-179
ncarol.com/10127242

Trending...
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Santa Your Way Announces Official 2026 Q4 Holiday Tour: Booking Open For Santa, The 5-star Grinch, And Dual Character Experiences Nationwide
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
Curtana Pharmaceuticals
AUSTIN, Texas - ncarol.com -- Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that it has signed an agreement with Catalent to support tablet formulation and manufacturing of Curtana's CT-179, a drug therapy for the treatment of glioblastoma (GBM), medulloblastoma (MB), and other brain cancers.

CT-179 is a highly potent and selective small molecule inhibitor of OLIG2, a transcription factor that is essential to normal early brain development but is not actively expressed in most normal adult brain cells or in normal tissues outside the brain. However, it is expressed in all diffuse gliomas and it has been shown that OLIG2 drives tumor initiation, tumor growth, invasion into healthy brain tissue, and resistance to chemotherapy and radiation therapy. Studies to-date have demonstrated the viability of CT-179 to markedly prolong survival in numerous, relevant animal models of GBM, MB and other brain cancers. The drug is orally bioavailable, readily crosses the blood-brain barrier, and achieves high concentrations in the brain.

"This is a significant milestone for the company as we move into clinical trials, which are anticipated to commence in the first half of 2022," said Gregory Stein, M.D., M.B.A. and Chief Executive Officer, Curtana Pharmaceuticals. "GBM is a devastating disease with a poor prognosis and a variety of therapeutic challenges. We are excited to bring this easy-to-use oral therapy with the potential to improve quality of life and prolong survival of patients with GBM and other devastating brain cancers."

More on ncarol.com
  • JoCa's Echoes of Haworth Sells Out on Opening Night in Mexico City; Artist Heads to San Luis Potosí and Miami Art Week
  • Alvear Homes Explains NC vs. SC Property Taxes for Charlotte-Area Homebuyers in 2026
  • Home2 Suites by Hilton Lee's Summit, MO Opens to Guests
  • Shanghai Chengwei Semiconductor Equipment Launches High Precision Laboratory Central Gas Supply System
  • Your Local Pro Expands National Service Network to 273+ Locations Across Plumbing, Cleaning, Landscaping and Hydrovac

Formulation development and CGMP manufacturing of the clinical trial product will take place at Catalent's 98,000 square-foot facility in San Diego, CA. This facility offers an array of services that support oral and injectable dosage forms that include preformulation testing, formulation and analytical development, CGMP manufacturing, clinical packaging, labeling, and worldwide distribution.

"Catalent is proud to partner with Curtana in the pursuit of a treatment for brain cancer," said Bryan Knox, General Manager of Catalent San Diego. "The Catalent team in San Diego is focused on early-stage development of small molecule and peptide drug candidates, from the bench to the clinic, and our expertise in oral delivery makes us an ideal partner for Curtana on the further development of CT-179."

About CT-179

FDA Orphan Drug designation for the treatment of malignant gliomas, including glioblastoma (GBM), was granted to CT-179 in August 2017. FDA Rare Pediatric Disease Designation for the treatment of medulloblastoma was granted to CT-179 in September 2020. The drug is orally bioavailable, readily crosses the blood-brain barrier, achieves very high concentrations in the brain, and significantly prolongs survival in animal models of brain cancer. CT-179 represents a novel agent which selectively targets OLIG2-expressing brain cancer cells in preclinical studies with great potential as an adjunctive therapy in the treatment of GBM, MB, and other brain cancers. An investigational new drug (IND) application filing is planned for the first half of 2022.

More on ncarol.com
  • Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
  • Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
  • KayeDinero Took Her Voice Off the Beat — And Says the Music Got More Personal
  • Solid Earth's new "Welcome to Real Estate" campaign introduces RealtyID™: Know Before Your Open the Door
  • KayeDinero Didn't Stop Writing. She Stopped Putting Words on the Beat

About Curtana Pharmaceuticals

Curtana Pharmaceuticals, founded in 2013, is a privately held, preclinical-stage biopharmaceutical company headquartered in Austin, Texas. Current investors include Thynk Capital, angelMD, Biosense Global, DEFTA Partners, and other anonymous investors. In 2014, the company was awarded a $7.6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Curtana focuses on the development of novel first-in-class, small molecule therapeutics targeting cancer stem cells in the central nervous system for the treatment of glioblastoma, medulloblastoma, and other brain cancers. For more information, visit www.curtanapharma.com.

Contact
Gregory Stein, M.D., M.B.A
***@curtanapharma.com


Source: Curtana Pharmaceuticals
Filed Under: Health, Manufacturing

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Las Vegas Attorney Thomas Boley Publishes Free Plain-English Guide to 100 Nevada Criminal Laws, in English and Spanish
  • Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing
  • NYC Big Book Award Celebrates 10th Anniversary with Announcement of 2026 Winners
  • Regional Magazines Shine at IRMA Awards
  • Nearly Two Years After Helene, KayeDinero Films Asheville's French Broad From Above
  • Asheville Producer KayeDinero Says "Human Error" Is the Point in the AI Music Era
  • Matt Zavala of Zavala Law, PC Selected to the 2027 Super Lawyers List
  • KayeDinero's "Glizzy Glock" Isn't What You Think — It Started With Late-Night Hot Dogs
  • Sawgrass Ford President Attributes Dealerships Success to Long-Term Employees
  • Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Santa Your Way Announces Official 2026 Q4 Holiday Tour: Booking Open For Santa, The 5-star Grinch, And Dual Character Experiences Nationwide
  • Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Headline: House of Nova Paints Every Face in Gold at New York Fashion Week
  • Can Government Operate Better Through Innovation?
  • Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
  • She Writes Python and Produces Music. KayeDinero Has a Question About AI Artists
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
_catLbl0 _catLbl1

Popular on ncarol.com

  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again - 172
  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing - 170
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not - 152
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 136
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History - 135
  • From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners - 131
  • Bspin Launches Lightning-Fast Crypto Gaming Expansion With Sportsbook, Poker, VIP Rewards, and Bitcoin Lightning Network Integration - 130
  • Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million - 125
  • Gigasoft 2026 JavaScript Chart Comparison: ProEssentials, Highcharts, SciChart, LightningChart, ECharts - 123
  • Steve Thompson Launches StickyHealth to Tackle the Retention Gap in the Growing GLP 1 Market - 118

Similar on ncarol.com

  • AMR and UAS Take the Stage at WorldSkills Shanghai 2026
  • Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
  • Shanghai Chengwei Semiconductor Equipment Launches High Precision Laboratory Central Gas Supply System
  • Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
  • JEGS Launches Transformed Digital Commerce Platform Powered by PhaseZero
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute